Archangels - Making The Future

Decision Process

Assuming that the basic criteria for investment are met and that the company has decided that it is seeking equity investment then the following process will be undertaken.

  • The executive will review the business plan and let the company know  whether or not the proposal will be considered further.
  • If it is not suitable for Archangels, we will try and suggest other potential investment sources.
  • If it is considered to be suitable for further investigation, then a meeting will be held with the management team to discuss the plan and the needs of the company.
  • If there is still interest, then some basic due diligence will be undertaken and other members of the syndicate may become involved in the assessment.
  • The company will be asked to present to the Board of Archangels.
  • The investment and other resource needs of the company will be discussed and agreed and an outline deal structure will be set out.
  • Appropriate due diligence and preparation of standard investment agreements etc will commence in parallel.
  • The company will normally be asked to present to a forum of interested potential investor members.
  • A non-executive chairman and a further non-executive director will be identified and agreed with the management team.
  • Any debt or grant requirements will be finalised.
  • Completion of the investment will proceed.
  • Archangels endeavour to keep deal costs low, charging upon completion of a successful funding round a research fee to cover due diligence and the initial investment. We also use low cost standard legal agreements which keep the legal fees payable by the company for completion of an investment to a minimum. There is a modest annual fee to the companies to cover the costs of ongoing monitoring and liaison.

Latest News

SCOTTISH SMES ANNOUNCE COLLABORATION TO ASSIST IN ESTABLISHMENT OFSTRATIFIED MEDICINE SCOTLAND INNOVATION CENTRE

23 Apr 2013
Today Scotland’s First Minister Alex Salmond announced the creation of a £20M Stratified Medicine Scotland Innovation Centre (SMS-IC), an initiative to grow Scotland’s reputation as a world leader in the conduct of “smart” clinical trials.

In the simplest terms, stratified medicine is about delivering “the right therapy, for the right patient, in the right dose, at the right time”. It is a medical model using clinical information and molecular profiling technologies to tailor therapeutic strategies and to determine the predisposition to disease at the population level. It enables the delivery of timely and stratified care pathways, monitoring, treatment and prevention.

Touch Bionics unveils next generation prosthetic hand with powered thumb rotation

12 Apr 2013
Touch Bionics, a provider of world-leading prosthetic technologies, today announced a significant advance to the company's groundbreaking i-limbTM technology. The i-limb ultra revolution, featuring a powered rotating thumb, 24 grip options and extra sensitive electrodes, is the first upper limb prosthesis that can be controlled via a mobile application.

£500,000 invested in revolutionary Scottish IT software, ZoneFox

08 Apr 2013
A Scottish IT firm has received over half a million pounds of fresh investment from the angel community and the Scottish Investment Bank, the investment arm of Scottish Enterprise, which will enable the accelerated development of its innovative data security software product, ZoneFox, the flagship product of Edinburgh-based Inquisitive Systems.

£3.25m invested in LUX Assure, a corrosion management company for the oil and gas industry

18 Feb 2013
Technology business LUX Assure has received £3.25m to transform the company from a technology development business to a service provider for the oil and gas industry. The investment comes from ConocoPhillips; Statoil Technology Invest AS; Archangel Informal Investment (Archangels); and the Scottish Investment Bank (SIB), a division of Scottish Enterprise.

Business angels given special recognition

15 Feb 2013
Archangel Informal Investment has been given special recognition after investing millions of pounds in Scottish companies and providing much-needed cash injections for some of the country’s most exciting life science projects